BUY Aurobindo Pharma — IDBI Capital, 03 Jul 2026

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))3 Jul 2026via IDBI Capital Research Calls Telegram

Entry₹1,610Stated

Target₹1,660

Stop loss₹1,583-1.68% risk

Exit₹1,5837 Jul 2026, 10:15 am

Stop-loss hit-1.68%

Follow IDBI Capital for new calls(28% target hit, 200 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 4 active Swing calls on AUROPHARMA See 261 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 9 Sept, 6:48 pm IST

6 supporting0 opposing

Supports the BUY call (6)

Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma, has completed the acquisition of Lannett.

NSE · Acquisition·30 Jun · 1w ago

Aurobindo Pharma Ltd has announced the completion of an acquisition.

BSE · Company Update·25 Jun · 2w ago

Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm

NSE · Acquisition·25 Jun · 2w ago

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·23 Jun · 2w ago

Aurobindo Pharma USA has received approval from the FTC to acquire Lannett Company, a significant strategic move for the company.

NSE · Press Release·22 Jun · 2w ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.